Last reviewed · How we verify
Colotox (BILIRUBIN)
At a glance
| Generic name | BILIRUBIN |
|---|---|
| Sponsor | BioActive Nutritional, Inc. |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- flatulence associated with constipation
Common side effects
Key clinical trials
- Urine and Ultrasound Screening for Kidney Disease in Children (NA)
- Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
- Relationship Between Delayed Cord Clamping at Birth and Neonatal Bilirubin Levels in Parturients With a Prior Child Requiring Therapy for Neonatal Jaundice (NA)
- Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation (PHASE2)
- Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome (PHASE2)
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment (PHASE1)
- Tolerability of Enteral NAC in Infants (PHASE1)
- Role of ICCO Score in Predicting Outcome in ICU Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colotox CI brief — competitive landscape report
- Colotox updates RSS · CI watch RSS
- BioActive Nutritional, Inc. portfolio CI